ORLANDO, Fla., May 14, 2021 /PRNewswire/ -- MicroGen
Diagnostics , the industry leader in providing next generation
DNA sequencing (NGS) for clinical diagnostics, has been
selected for a study evaluating the impact of space travel on
the human urinary microbiome. The research will be conducted during
the 2022 Israeli Rakia Space
Mission to the International Space station (ISS).
will use both its 16s and its full genomic sequencing in the study.
Researchers Seek Solutions to Astronauts' Urinary Tract Infections
During Space Travel
"We're honored and excited to be part of this study to evaluate
the impact of space travel on the urinary microbiome," says
Rick Martin, CEO of MicroGenDX.
"MicroGenDX is uniquely qualified to provide this data for analysis
that could be the basis for future solutions to astronaut medical
care. This work will help shape the future of long-term space
missions — including the multi-year Mars mission."
According to current research, the frequency and severity of
urinary tract infections (UTIs) can increase for astronauts
during space travel. Microgravity, changes in the urinary
microbiome, immune system dysregulation, urinary retention and
other consequences of space travel appear to have an impact on
the incidence, severity, and treatment of UTIs. This
urinary microbiome study will provide a critical opportunity
to better understand these factors.
Paul H. Chung, M.D., assistant
professor of urology at Thomas Jefferson
University in Philadelphia,
Penn., will lead the team of university and medical
researchers from multiple countries in evaluating the data
MicroGenDX. The team includes Javad Parvizi, M.D. and Emanuele Chisari, M.D. from Rothman Orthopedics,
Thomas Jefferson University; Ben
Boursi, M.D., from Sheba Medical Center, Tel Aviv, Israel; Caleb Philips, Ph.D.
from Texas Tech University,
Lubbock, Tex., and J. Curtis Nickel, Ph.D., from Queens
University, Kingston Ontario, Canada.
research is being funded by the Ramon-Rakia Space Mission.
Founded in 2008,
MicroGenDX has become the industry leader in rapid turnaround
and affordability for comprehensive qPCR and next-generation
sequencing (NGS) testing for clinical diagnostics. MicroGenDX
has been the trusted research partner for the CDC, U.S. Army,
Johnson & Johnson, Mayo Clinic, NASA and the
FDA. MicroGenDX has published more than 35 clinical trials and
is the most experienced molecular
diagnostic laboratory with nearly
1.5 million samples processed.
Media Contact: James
Compagno email@example.com 407.863.0043
SOURCE MicroGen DX